Engineered calmodulin for treatment of ryanopathies
US10214574B2 · kind B2 · utility
0Cited by
3References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 2016 |
| Grant date | Feb 26, 2019 |
| Priority date | — |
| Expiry date | Apr 15, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are disclosed for altering the binding affinity of calmodulin for ryanodine receptor 2 (RyR2). As disclosed herein, these therapeutic calmodulin (TCaM) proteins can be used to correct ryanopathies by prolonging the RyR2 refractory period. Therefore, also disclosed is a method for treating a ryanopathy-associated disease in a subject that involves administering to the subject a composition comprising a TCaM disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.